The active substance attracts most attention, but excipients, solvents and metals in the formulation are reviewed just as closely, and each has its own place in Module 3.
Excipients in section 3.2.P.4
Section 3.2.P.4 covers the specifications of excipients, the analytical procedures and, for novel excipients, full information equivalent to that for an active substance. Most excipients comply with a pharmacopoeial monograph, which is accepted as the specification, but additional tests may be needed where the function in the product requires it, for example particle size or viscosity.
Excipients of human or animal origin need attention to transmissible spongiform encephalopathy risk, usually through a TSE certificate or a statement of the source. Where an excipient contains a colourant or a preservative, the permitted use and levels should be confirmed.
Residual solvents
ICH Q3C classifies solvents by toxicity and sets permitted daily exposures. Residual solvents arising in the active substance are controlled at that level, while solvents used in finished product manufacture are evaluated in the context of the product. Class 1 solvents should be avoided unless strongly justified.
Elemental impurities
ICH Q3D takes a risk-based approach to elemental impurities in the drug product. The applicant identifies potential sources, including active substance, excipients, equipment and the container closure system, and assesses whether the permitted daily exposure for the route of administration could be exceeded.
- The assessment can be based on data from suppliers, literature or product testing.
- Testing of every batch is not always required if control is justified by risk assessment.
- The conclusion and supporting data should be summarised in the quality sections.
Why these controls matter together
Impurity controls in the dossier work as a system. A nitrosamine risk assessment, a Q3D assessment and a residual solvent evaluation draw on the same supplier information, and inconsistent answers in each are a recurring cause of questions. Collecting supplier declarations once and using them across all assessments saves time and reduces contradictions.
Common pitfalls
- Relying on a pharmacopoeial monograph without checking functionality-related tests.
- Missing TSE information for excipients of animal origin.
- A Q3D assessment that ignores the container closure system.
- Supplier statements that are out of date or do not cover the site in use.
Building one assessment for several guidelines
Create a single supplier information request that covers nitrosamines, residual solvents, elemental impurities and animal-origin materials in one document. Suppliers respond more reliably to one structured request than to four separate ones, and the answers can then be mapped into each assessment. Keep the responses on file with dates, since they support both the dossier and later inspections.
How PQRA helps
PQRA reviews excipient documentation, assembles and checks risk assessments for solvents, elemental impurities and nitrosamines, and ensures the conclusions are reflected consistently across Module 3.
Talk to us about your dossier: Contact PQRA


No responses yet